🇺🇸 FDA
Pipeline program

LEAn Body Mass Normalization of OXaliplatin Based Chemotherapy

ICM-URC2016/27

Phase 2 other active

Quick answer

LEAn Body Mass Normalization of OXaliplatin Based Chemotherapy for Colon cancer is a Phase 2 program (other) at Institut für biomedizinische Analytik NMR-Imaging GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Institut für biomedizinische Analytik NMR-Imaging GmbH
Indication
Colon cancer
Phase
Phase 2
Modality
other
Status
active

Clinical trials